Valuation: Crinetics Pharmaceuticals, Inc.

Market Cap 8.9B 7.7B 7.19B 6.6B 12.41B 847B 12.6B 84.36B 33.11B 425B 33.43B 32.69B 1,404B P/E 2026 *
-17.8x
P/E 2027 * -20.1x
Enterprise Value 7.87B 6.8B 6.35B 5.83B 10.96B 749B 11.14B 74.55B 29.26B 375B 29.54B 28.89B 1,240B EV / Sales 2026 *
134x
EV / Sales 2027 * 46.7x
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
1 day-0.07%
1 week+0.44%
Current month+0.44%
1 month+0.42%
3 months+92.88%
6 months+82.32%
Current year+80.20%
1 week 83.62
Extreme 83.62
84.08
1 month 83.44
Extreme 83.44
84.08
Current year 32.3
Extreme 32.3
84.08
1 year 25.83
Extreme 25.83
84.08
3 years 15.76
Extreme 15.76
84.08
5 years 15.23
Extreme 15.23
84.08
10 years 10.63
Extreme 10.63
84.08
Manager TitleAgeSince
Chief Executive Officer 64 2008-11-30
Chief Tech/Sci/R&D Officer 60 2021-09-30
Director of Finance/CFO 51 2025-02-27
Director TitleAgeSince
Chairman 78 2015-09-30
Director/Board Member 64 2008-10-31
Director/Board Member 61 2018-01-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Director

-3,000 0.0028%
3/12/26 Sell

Director

5,000 0.0048%
2/23/26 Free

Chief Financial Officer

82,000 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+0.44%+200.88%+366.03% 8.9B
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.44%+32.55%+72.63% 54.32B
+2.65%+3.13%-16.11%-5.16% 22.91B
-0.72%+33.25%+20.20%+500.73% 28.73B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+7.56%+38.20%-21.33% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+2.86%+0.62%+42.71%+163.51% 13.12B
Average +3.40%+6.72%+65.85%+216.33% 26.23B
Weighted average by Cap. +4.03%+9.62%+52.82%+173.11%

Financials

2026 *2027 *
Net sales 58.81M 50.87M 47.51M 43.58M 81.97M 5.6B 83.27M 557M 219M 2.81B 221M 216M 9.27B 172M 149M 139M 128M 240M 16.39B 244M 1.63B 641M 8.21B 647M 632M 27.15B
Net income -516M -447M -417M -383M -720M -49.15B -731M -4.89B -1.92B -24.64B -1.94B -1.9B -81.45B -473M -409M -382M -350M -659M -44.98B -669M -4.48B -1.76B -22.54B -1.77B -1.74B -74.53B
Net Debt -1.04B -895M -836M -767M -1.44B -98.51B -1.47B -9.81B -3.85B -49.37B -3.89B -3.8B -163B -865M -748M -699M -641M -1.21B -82.34B -1.23B -8.2B -3.22B -41.27B -3.25B -3.18B -136B
Logo Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Date Price Change Volume
26-08-07 US$83.88 -0.05% 1,080,799
26-08-06 US$83.92 -0.10% 2,096,262
26-08-05 US$84.00 +0.17% 2,866,831
26-08-04 US$83.86 +0.12% 2,725,922
26-08-03 US$83.76 +0.29% 1,745,072
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
83.92USD
Average target price
85.50USD
Spread / Average Target
+1.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNX Stock